Product Details
Product Name:
EPAC 5376753 |
CAS No.:
302826-61-5 |
Purity:
90% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | EPAC 5376753 |
Description | EPAC 5376753 is an allosteric inhibitor of EPAC1 with an IC50 of 4 µM in Swiss 3T3 cells. |
In vitro | EPAC 5376753 decreases the conformational changes of EPAC necessary for its activation. EPAC 5376753 inhibits EPAC signaling in cells and EPAC-mediated migration in fibroblasts[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 3.68 mg/mL (10.01 mM)
|
Keywords | EPAC 5376753 | EPAC5376753 | EPAC-5376753 |
Inhibitors Related | UNC0006 | Bithionol | HJC0197 | Adenosine receptor A1 antagonist 5 | HJC0350 | TDI-10229 | I942 | MRE3008F20 | Torbafylline | 2-PCCA hydrochloride | ESI-05 | GAT211 |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1702428-31-6
$50.00 / 5mg
-
CAS:7081-44-9
$30.00 / 200mg
-
CAS:145-41-5
$42.00 / 500mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$44.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |